- BriaCell Therapeutics and Incyte have formed a non-exclusive clinical trial collaboration to evaluate the effects
of combinations of novel clinical candidates
- Under the agreement, Incyte will provide compounds from its development portfolio, including INCMGA0012, an
anti-PD-1 monoclonal antibody, and epacadostat, an IDO1 inhibitor, for use in combination studies with BriaCell’s lead
candidate, Bria-IMT™, in advanced breast cancer patients
BERKELEY, Calif., and VANCOUVER, British Columbia, April 02, 2019 (GLOBE NEWSWIRE) --
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage
biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced a clinical trial
collaboration and supply agreement (the “Agreement”) with Incyte (NASDAQ:INCY), a global biopharmaceutical company focused on
discovering and developing novel therapeutics in oncology and other serious diseases.
The Agreement is focused on, but not limited to, the selection of novel combinations for the treatment of
advanced breast cancer along with a planned clinical study of BriaCell’s lead candidate, Bria-IMT™, with Incyte’s selected
compounds for advanced breast cancer.
Under the terms of the Agreement, BriaCell will evaluate combinations of novel therapeutics for the
treatment of patients with advanced breast cancer. Incyte will provide BriaCell with selected novel compounds to be used in the
planned combination study with Bria-IMT™.
"It is our belief that checkpoint inhibitors may significantly amplify the tumor-reducing effects of BriaCell’s
novel immunotherapy, Bria-IMT™, in advanced breast cancer patients. Incyte’s portfolio has several candidates, including an
anti-PD-1 monoclonal antibody and an IDO1 inhibitor, that we hope will improve the clinical benefits of Bria-IMT™," stated Dr.
Bill Williams, BriaCell’s President and Chief Executive Officer. "Incyte is a world-class biopharmaceutical company, we are aligned
with the value that the team there places on innovation and we look forward to working with Incyte’s scientists and clinical
experts to develop novel therapeutics for advanced breast cancer patients.”
About BriaCell
BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the
management of cancer.
BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT™, its lead candidate, in a combination
study with pembrolizumab [KEYTRUDA®; manufactured by Merck & Co., Inc. (NYSE: MRK)]. The combination study is listed in
ClinicalTrials.gov as NCT03328026.
BriaCell is developing Bria-OTS™, an off-the-shelf personalized immunotherapy, for advanced breast cancer.
Bria-OTS™ immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing.
Bria-OTS™, which is expected to cover over 99 percent of the patient population, is designed to produce a potent and selective
immune response against the cancer of each patient while eliminating the time, expense and complex manufacturing logistics
associated with other personalized immunotherapies.
For additional information on BriaCell, please visit: https://briacell.com.
Cautionary Note Regarding Forward-Looking Information
Except for the statements of historical fact, this news release contains "forward-looking information" within
the meaning of the applicable Canadian securities legislation which involves known and unknown risks relevant to the Company in
particular and to the biotechnology and pharmaceutical industries in general, uncertainties and other factors that may cause actual
events to differ materially from current expectation. These risks are more fully described in the Company's public filings
available at www.sedar.com.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of
the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update
or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of
the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
For further information, please contact:
BriaCell Therapeutics Corp.:
Farrah Dean
Manager, Corporate Development
Email: Farrah@BriaCell.com
Phone: 1-888-485-6340
